You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system

    SBC: FasCure Therapeutics LLC            Topic: NIAID

    DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Activin A Antagonists for Treatment of Osteoporosis

    SBC: ABREOS BIOSCIENCES, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Bone loss and fragility from osteoporosis afflict more than million people worldwide including at least million Americans Current osteoporosis treatments are significantly deficient most fail to reverse bone loss and or have adverse effects that prohibit their long term use New therapeutic approaches are urgently needed Recently the TGF family li ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells

    SBC: ZoneOne Pharma            Topic: O

    DESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. A dual-polarized Doppler Radar system for fall detection in an indoor environment

    SBC: MS Technologies Corporation            Topic: NIA

    DESCRIPTION provided by applicant Falls are a leading cause of injuries and deaths among older adults OAs and will be an increasing public health concern given projections of future increases in the number of OAs in the US Fall detection and or surveillance systems are needed to enhance an OAandapos s confidence and independence and to facilitate rapid post fall responses This project wil ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Therapeutics to Treat Candida albicans Biofilm Infections

    SBC: BIOSYNESIS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The yeast Candida albicans is a normal resident of the human digestive tract It is also the most common fungal pathogen of humans causing both mucosal and systemic infections particularly in immune compromised individuals The majority of new C albicans infections arise from the presence of persistent C albicans cells existing in a biofilm These biofilm b ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Urine Diagnostics for Aspergillosis

    SBC: PEARL DIAGNOSTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Aspergillosis is a severe fungal infection that most frequently involves the lungs in people who have immune deficiency caused by cancer chemotherapy and or transplantation Although good drugs are available establishing a diagnosis is difficult and late treatment has limited our progress in decreasing morbidity and mortality We observed that Aspergillus pol ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. A Protective Tetravalent Vaccine Candidate for Dengue Fever Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION provided by applicant There are approximately million cases of dengue fever each year with billion people at risk mostly in low income countries There are four serotypes of dengue fever virus DENV and in its uncomplicated form the disease is worthy of its indigenous name andquot break bone feverandquot An individual may suffer sequential infections with multiple DE ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Rapid Diagnostics for Mucormycosis

    SBC: VITALEX BIOSCIENCES, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Mucormycosis most commonly caused by Rhizopus oryzae is a life threatening infection that occurs in patients immunocompromised by diabetic ketoacidosis DKA neutropenia corticosteroid use and or increased serum iron Because of the rising prevalence of these risk factors the incidence of mucormycosis has risen Despite disfiguring surgery and aggressive ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Selective inhibitors of Heme Transporters as Antiparasitic Agents

    SBC: RAKTA THERAPEUTICS INC            Topic: NIAID

    DESCRIPTION provided by applicant Neglected Tropical Diseases NTD which include helminthiasis and leishmaniasis are a group of thirteen parasitic and bacterial infections that affect over billion people Although these are devastating diseases of global concern their neglected status relative to other health concerns has resulted in a limited arsenal of therapeutic compounds for their ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government